JP2008540635A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008540635A5 JP2008540635A5 JP2008511821A JP2008511821A JP2008540635A5 JP 2008540635 A5 JP2008540635 A5 JP 2008540635A5 JP 2008511821 A JP2008511821 A JP 2008511821A JP 2008511821 A JP2008511821 A JP 2008511821A JP 2008540635 A5 JP2008540635 A5 JP 2008540635A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- methanone
- oxadiazol
- fluoro
- piperidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 208000015114 central nervous system disease Diseases 0.000 claims 9
- 208000012902 Nervous system disease Diseases 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 4
- 206010012289 Dementia Diseases 0.000 claims 4
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 4
- 201000000980 schizophrenia Diseases 0.000 claims 4
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 3
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 208000007848 Alcoholism Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 206010012218 Delirium Diseases 0.000 claims 2
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 2
- 125000002877 alkyl aryl group Chemical group 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000029364 generalized anxiety disease Diseases 0.000 claims 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 230000036651 mood Effects 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 230000003287 optical effect Effects 0.000 claims 2
- -1 oxadiazol-3-yl Chemical group 0.000 claims 2
- 230000002085 persistent effect Effects 0.000 claims 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- MFACHGPNTFMTRE-LBPRGKRZSA-N (2,3-difluorophenyl)-[(3s)-3-(5-pyridin-2-yl-1,2,4-oxadiazol-3-yl)piperidin-1-yl]methanone Chemical compound FC1=CC=CC(C(=O)N2C[C@H](CCC2)C=2N=C(ON=2)C=2N=CC=CC=2)=C1F MFACHGPNTFMTRE-LBPRGKRZSA-N 0.000 claims 1
- RZKPASPGSLBRFH-UHFFFAOYSA-N (2,4-difluorophenyl)-[3-(5-phenyl-1,2,4-oxadiazol-3-yl)piperidin-1-yl]methanone Chemical compound FC1=CC(F)=CC=C1C(=O)N1CC(C=2N=C(ON=2)C=2C=CC=CC=2)CCC1 RZKPASPGSLBRFH-UHFFFAOYSA-N 0.000 claims 1
- QLDMKJGNOKEKQX-UHFFFAOYSA-N (2,4-difluorophenyl)-[3-(5-pyridin-4-yl-1,2,4-oxadiazol-3-yl)piperidin-1-yl]methanone Chemical compound FC1=CC(F)=CC=C1C(=O)N1CC(C=2N=C(ON=2)C=2C=CN=CC=2)CCC1 QLDMKJGNOKEKQX-UHFFFAOYSA-N 0.000 claims 1
- FVLYACNSOCNXOP-UHFFFAOYSA-N (2,4-difluorophenyl)-[3-[5-(2,4-difluorophenyl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]methanone Chemical compound FC1=CC(F)=CC=C1C(=O)N1CC(C=2N=C(ON=2)C=2C(=CC(F)=CC=2)F)CCC1 FVLYACNSOCNXOP-UHFFFAOYSA-N 0.000 claims 1
- QHJPIBZJKPKBGD-UHFFFAOYSA-N (2,4-difluorophenyl)-[3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]methanone Chemical compound FC1=CC(F)=CC=C1C(=O)N1CC(C=2N=C(ON=2)C=2C(=CC=CC=2)F)CCC1 QHJPIBZJKPKBGD-UHFFFAOYSA-N 0.000 claims 1
- XQXYXEFVLBRRLK-UHFFFAOYSA-N (2,4-difluorophenyl)-[3-[5-(4-fluorophenyl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]methanone Chemical compound C1=CC(F)=CC=C1C1=NC(C2CN(CCC2)C(=O)C=2C(=CC(F)=CC=2)F)=NO1 XQXYXEFVLBRRLK-UHFFFAOYSA-N 0.000 claims 1
- NPMRXXFOHLUBCQ-LBPRGKRZSA-N (2,5-difluorophenyl)-[(3s)-3-(5-pyridin-2-yl-1,2,4-oxadiazol-3-yl)piperidin-1-yl]methanone Chemical compound FC1=CC=C(F)C(C(=O)N2C[C@H](CCC2)C=2N=C(ON=2)C=2N=CC=CC=2)=C1 NPMRXXFOHLUBCQ-LBPRGKRZSA-N 0.000 claims 1
- BTOBLUWDUNIIJD-LBPRGKRZSA-N (2,6-difluorophenyl)-[(3s)-3-(5-pyridin-2-yl-1,2,4-oxadiazol-3-yl)piperidin-1-yl]methanone Chemical compound FC1=CC=CC(F)=C1C(=O)N1C[C@@H](C=2N=C(ON=2)C=2N=CC=CC=2)CCC1 BTOBLUWDUNIIJD-LBPRGKRZSA-N 0.000 claims 1
- VNJXMBOXANPIOR-ZDUSSCGKSA-N (3,4-difluorophenyl)-[(3s)-3-(5-pyridin-2-yl-1,2,4-oxadiazol-3-yl)piperidin-1-yl]methanone Chemical compound C1=C(F)C(F)=CC=C1C(=O)N1C[C@@H](C=2N=C(ON=2)C=2N=CC=CC=2)CCC1 VNJXMBOXANPIOR-ZDUSSCGKSA-N 0.000 claims 1
- XALAKXXAHSGBLG-LBPRGKRZSA-N (3,4-difluorophenyl)-[(3s)-3-[5-(3-fluoropyridin-4-yl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]methanone Chemical compound C1=C(F)C(F)=CC=C1C(=O)N1C[C@@H](C=2N=C(ON=2)C=2C(=CN=CC=2)F)CCC1 XALAKXXAHSGBLG-LBPRGKRZSA-N 0.000 claims 1
- JOQRZFQQFQSSLZ-AWEZNQCLSA-N (3,4-difluorophenyl)-[(3s)-3-[5-(4-fluorophenyl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]methanone Chemical compound C1=CC(F)=CC=C1C1=NC([C@@H]2CN(CCC2)C(=O)C=2C=C(F)C(F)=CC=2)=NO1 JOQRZFQQFQSSLZ-AWEZNQCLSA-N 0.000 claims 1
- FGNFVVDFFRGMRC-UHFFFAOYSA-N (3,4-difluorophenyl)-[3-(5-phenyl-1,2,4-oxadiazol-3-yl)piperidin-1-yl]methanone Chemical compound C1=C(F)C(F)=CC=C1C(=O)N1CC(C=2N=C(ON=2)C=2C=CC=CC=2)CCC1 FGNFVVDFFRGMRC-UHFFFAOYSA-N 0.000 claims 1
- NCOQAHWYGXNMCO-UHFFFAOYSA-N (3,4-difluorophenyl)-[3-(5-pyridin-4-yl-1,2,4-oxadiazol-3-yl)piperidin-1-yl]methanone Chemical compound C1=C(F)C(F)=CC=C1C(=O)N1CC(C=2N=C(ON=2)C=2C=CN=CC=2)CCC1 NCOQAHWYGXNMCO-UHFFFAOYSA-N 0.000 claims 1
- BIQBTTAKDWADJF-UHFFFAOYSA-N (3,4-difluorophenyl)-[3-[5-(2,4-difluorophenyl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]methanone Chemical compound FC1=CC(F)=CC=C1C1=NC(C2CN(CCC2)C(=O)C=2C=C(F)C(F)=CC=2)=NO1 BIQBTTAKDWADJF-UHFFFAOYSA-N 0.000 claims 1
- LYJOIMLTBRZHLS-UHFFFAOYSA-N (3,4-difluorophenyl)-[3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]methanone Chemical compound C1=C(F)C(F)=CC=C1C(=O)N1CC(C=2N=C(ON=2)C=2C(=CC=CC=2)F)CCC1 LYJOIMLTBRZHLS-UHFFFAOYSA-N 0.000 claims 1
- JOQRZFQQFQSSLZ-UHFFFAOYSA-N (3,4-difluorophenyl)-[3-[5-(4-fluorophenyl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]methanone Chemical compound C1=CC(F)=CC=C1C1=NC(C2CN(CCC2)C(=O)C=2C=C(F)C(F)=CC=2)=NO1 JOQRZFQQFQSSLZ-UHFFFAOYSA-N 0.000 claims 1
- IDSAHSUKHOIREH-AWEZNQCLSA-N (3,5-dimethyl-1,2-oxazol-4-yl)-[(3s)-3-[5-(4-fluorophenyl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]methanone Chemical compound CC1=NOC(C)=C1C(=O)N1C[C@@H](C=2N=C(ON=2)C=2C=CC(F)=CC=2)CCC1 IDSAHSUKHOIREH-AWEZNQCLSA-N 0.000 claims 1
- OCGFOXVGAPMIGP-UHFFFAOYSA-N (4-fluoro-2-methylphenyl)-[3-(5-pyridin-4-yl-1,2,4-oxadiazol-3-yl)piperidin-1-yl]methanone Chemical compound CC1=CC(F)=CC=C1C(=O)N1CC(C=2N=C(ON=2)C=2C=CN=CC=2)CCC1 OCGFOXVGAPMIGP-UHFFFAOYSA-N 0.000 claims 1
- IHUDYVXRCOHGFM-UHFFFAOYSA-N (4-fluoro-2-methylphenyl)-[3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]methanone Chemical compound CC1=CC(F)=CC=C1C(=O)N1CC(C=2N=C(ON=2)C=2C(=CC=CC=2)F)CCC1 IHUDYVXRCOHGFM-UHFFFAOYSA-N 0.000 claims 1
- AFWZUWYKUAAWLK-UHFFFAOYSA-N (4-fluoro-2-methylphenyl)-[3-[5-(4-fluorophenyl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]methanone Chemical compound CC1=CC(F)=CC=C1C(=O)N1CC(C=2N=C(ON=2)C=2C=CC(F)=CC=2)CCC1 AFWZUWYKUAAWLK-UHFFFAOYSA-N 0.000 claims 1
- BMOHUBRAWYJENF-OAHLLOKOSA-N (4-fluorophenyl)-[(3r)-3-[5-(4-fluorophenyl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]methanone Chemical compound C1=CC(F)=CC=C1C(=O)N1C[C@H](C=2N=C(ON=2)C=2C=CC(F)=CC=2)CCC1 BMOHUBRAWYJENF-OAHLLOKOSA-N 0.000 claims 1
- SDQGSRQCLAPKJG-AWEZNQCLSA-N (4-fluorophenyl)-[(3s)-3-(5-pyridin-2-yl-1,2,4-oxadiazol-3-yl)piperidin-1-yl]methanone Chemical compound C1=CC(F)=CC=C1C(=O)N1C[C@@H](C=2N=C(ON=2)C=2N=CC=CC=2)CCC1 SDQGSRQCLAPKJG-AWEZNQCLSA-N 0.000 claims 1
- XTWVOXMALMSNNP-ZDUSSCGKSA-N (4-fluorophenyl)-[(3s)-3-[5-(1-methylimidazol-4-yl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]methanone Chemical compound CN1C=NC(C=2ON=C(N=2)[C@@H]2CN(CCC2)C(=O)C=2C=CC(F)=CC=2)=C1 XTWVOXMALMSNNP-ZDUSSCGKSA-N 0.000 claims 1
- BMOHUBRAWYJENF-HNNXBMFYSA-N (4-fluorophenyl)-[(3s)-3-[5-(4-fluorophenyl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]methanone Chemical compound C1=CC(F)=CC=C1C(=O)N1C[C@@H](C=2N=C(ON=2)C=2C=CC(F)=CC=2)CCC1 BMOHUBRAWYJENF-HNNXBMFYSA-N 0.000 claims 1
- BPFBFTDBSMZRGT-ZDUSSCGKSA-N (4-fluorophenyl)-[(3s)-3-[5-(5-fluoropyridin-2-yl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]methanone Chemical compound C1=CC(F)=CC=C1C(=O)N1C[C@@H](C=2N=C(ON=2)C=2N=CC(F)=CC=2)CCC1 BPFBFTDBSMZRGT-ZDUSSCGKSA-N 0.000 claims 1
- WCAKDPMJJRBDTL-UHFFFAOYSA-N (4-fluorophenyl)-[3-(5-phenyl-1,2,4-oxadiazol-3-yl)piperidin-1-yl]methanone Chemical compound C1=CC(F)=CC=C1C(=O)N1CC(C=2N=C(ON=2)C=2C=CC=CC=2)CCC1 WCAKDPMJJRBDTL-UHFFFAOYSA-N 0.000 claims 1
- SDQGSRQCLAPKJG-UHFFFAOYSA-N (4-fluorophenyl)-[3-(5-pyridin-2-yl-1,2,4-oxadiazol-3-yl)piperidin-1-yl]methanone Chemical compound C1=CC(F)=CC=C1C(=O)N1CC(C=2N=C(ON=2)C=2N=CC=CC=2)CCC1 SDQGSRQCLAPKJG-UHFFFAOYSA-N 0.000 claims 1
- IYKRLTJPTXKTEW-UHFFFAOYSA-N (4-fluorophenyl)-[3-(5-pyridin-4-yl-1,2,4-oxadiazol-3-yl)piperidin-1-yl]methanone Chemical compound C1=CC(F)=CC=C1C(=O)N1CC(C=2N=C(ON=2)C=2C=CN=CC=2)CCC1 IYKRLTJPTXKTEW-UHFFFAOYSA-N 0.000 claims 1
- RELHBNHQGFPRNS-UHFFFAOYSA-N (4-fluorophenyl)-[3-[5-(1,3-thiazol-4-yl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]methanone Chemical compound C1=CC(F)=CC=C1C(=O)N1CC(C=2N=C(ON=2)C=2N=CSC=2)CCC1 RELHBNHQGFPRNS-UHFFFAOYSA-N 0.000 claims 1
- IYGYBNPIOYQURC-UHFFFAOYSA-N (5-methyl-1,2-oxazol-4-yl)-[3-(5-pyridin-4-yl-1,2,4-oxadiazol-3-yl)piperidin-1-yl]methanone Chemical compound O1N=CC(C(=O)N2CC(CCC2)C=2N=C(ON=2)C=2C=CN=CC=2)=C1C IYGYBNPIOYQURC-UHFFFAOYSA-N 0.000 claims 1
- UEMNYOYZIFPSNE-UHFFFAOYSA-N (6-fluoropyridin-3-yl)-[3-(5-phenyl-1,2,4-oxadiazol-3-yl)piperidin-1-yl]methanone Chemical compound C1=NC(F)=CC=C1C(=O)N1CC(C=2N=C(ON=2)C=2C=CC=CC=2)CCC1 UEMNYOYZIFPSNE-UHFFFAOYSA-N 0.000 claims 1
- WLIHTKXCDWCBHS-UHFFFAOYSA-N (6-fluoropyridin-3-yl)-[3-(5-pyridin-2-yl-1,2,4-oxadiazol-3-yl)piperidin-1-yl]methanone Chemical compound C1=NC(F)=CC=C1C(=O)N1CC(C=2N=C(ON=2)C=2N=CC=CC=2)CCC1 WLIHTKXCDWCBHS-UHFFFAOYSA-N 0.000 claims 1
- OSINSSZHBSZOIJ-UHFFFAOYSA-N (6-fluoropyridin-3-yl)-[3-(5-pyridin-4-yl-1,2,4-oxadiazol-3-yl)piperidin-1-yl]methanone Chemical compound C1=NC(F)=CC=C1C(=O)N1CC(C=2N=C(ON=2)C=2C=CN=CC=2)CCC1 OSINSSZHBSZOIJ-UHFFFAOYSA-N 0.000 claims 1
- INHCWRWUIDYWQP-UHFFFAOYSA-N (6-fluoropyridin-3-yl)-[3-[5-(1,3-thiazol-4-yl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]methanone Chemical compound C1=NC(F)=CC=C1C(=O)N1CC(C=2N=C(ON=2)C=2N=CSC=2)CCC1 INHCWRWUIDYWQP-UHFFFAOYSA-N 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims 1
- 208000008811 Agoraphobia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000029197 Amphetamine-Related disease Diseases 0.000 claims 1
- 208000000103 Anorexia Nervosa Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 206010006550 Bulimia nervosa Diseases 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 208000022497 Cocaine-Related disease Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010012225 Delirium tremens Diseases 0.000 claims 1
- 208000024254 Delusional disease Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000027534 Emotional disease Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 102000012777 Metabotropic Glutamate 5 Receptor Human genes 0.000 claims 1
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 claims 1
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 claims 1
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 claims 1
- 206010057852 Nicotine dependence Diseases 0.000 claims 1
- 208000026251 Opioid-Related disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010067063 Progressive relapsing multiple sclerosis Diseases 0.000 claims 1
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 claims 1
- 208000028810 Shared psychotic disease Diseases 0.000 claims 1
- 206010041250 Social phobia Diseases 0.000 claims 1
- 208000011962 Substance-induced mood disease Diseases 0.000 claims 1
- 231100000395 Substance-induced mood disorder Toxicity 0.000 claims 1
- 208000011963 Substance-induced psychotic disease Diseases 0.000 claims 1
- 231100000393 Substance-induced psychotic disorder Toxicity 0.000 claims 1
- 208000025569 Tobacco Use disease Diseases 0.000 claims 1
- DZESYXLPYBNPAL-NSHDSACASA-N [(3s)-3-(5-pyridin-2-yl-1,2,4-oxadiazol-3-yl)piperidin-1-yl]-(2,3,4-trifluorophenyl)methanone Chemical compound FC1=C(F)C(F)=CC=C1C(=O)N1C[C@@H](C=2N=C(ON=2)C=2N=CC=CC=2)CCC1 DZESYXLPYBNPAL-NSHDSACASA-N 0.000 claims 1
- KTFIWOOCISQGRC-UHFFFAOYSA-N [3-[5-(2,4-difluorophenyl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]-(4-fluoro-2-methylphenyl)methanone Chemical compound CC1=CC(F)=CC=C1C(=O)N1CC(C=2N=C(ON=2)C=2C(=CC(F)=CC=2)F)CCC1 KTFIWOOCISQGRC-UHFFFAOYSA-N 0.000 claims 1
- DJAVMDAOUDNDQU-UHFFFAOYSA-N [3-[5-(2,4-difluorophenyl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]-(4-fluorophenyl)methanone Chemical compound C1=CC(F)=CC=C1C(=O)N1CC(C=2N=C(ON=2)C=2C(=CC(F)=CC=2)F)CCC1 DJAVMDAOUDNDQU-UHFFFAOYSA-N 0.000 claims 1
- YGIDNOCJVNXDSW-UHFFFAOYSA-N [3-[5-(2,4-difluorophenyl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]-(5-methyl-1,2-oxazol-4-yl)methanone Chemical compound O1N=CC(C(=O)N2CC(CCC2)C=2N=C(ON=2)C=2C(=CC(F)=CC=2)F)=C1C YGIDNOCJVNXDSW-UHFFFAOYSA-N 0.000 claims 1
- KURUNEQGYVJYTM-UHFFFAOYSA-N [3-[5-(2,4-difluorophenyl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]-(6-fluoropyridin-3-yl)methanone Chemical compound FC1=CC(F)=CC=C1C1=NC(C2CN(CCC2)C(=O)C=2C=NC(F)=CC=2)=NO1 KURUNEQGYVJYTM-UHFFFAOYSA-N 0.000 claims 1
- QHXQRXPAVCRUDZ-UHFFFAOYSA-N [3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]-(5-fluoropyridin-2-yl)methanone Chemical compound N1=CC(F)=CC=C1C(=O)N1CC(C=2N=C(ON=2)C=2C(=CC=CC=2)F)CCC1 QHXQRXPAVCRUDZ-UHFFFAOYSA-N 0.000 claims 1
- FFBAPHVNNSCKFP-UHFFFAOYSA-N [3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]-(5-methyl-1,2-oxazol-4-yl)methanone Chemical compound O1N=CC(C(=O)N2CC(CCC2)C=2N=C(ON=2)C=2C(=CC=CC=2)F)=C1C FFBAPHVNNSCKFP-UHFFFAOYSA-N 0.000 claims 1
- GMELVPSGYJKOAV-UHFFFAOYSA-N [3-[5-(4-fluorophenyl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]-(5-methyl-1,2-oxazol-4-yl)methanone Chemical compound O1N=CC(C(=O)N2CC(CCC2)C=2N=C(ON=2)C=2C=CC(F)=CC=2)=C1C GMELVPSGYJKOAV-UHFFFAOYSA-N 0.000 claims 1
- RSTNDKZTQBZOCY-UHFFFAOYSA-N [3-[5-(4-fluorophenyl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]-(6-fluoropyridin-3-yl)methanone Chemical compound C1=CC(F)=CC=C1C1=NC(C2CN(CCC2)C(=O)C=2C=NC(F)=CC=2)=NO1 RSTNDKZTQBZOCY-UHFFFAOYSA-N 0.000 claims 1
- YMBKQJYKSFUBLO-UHFFFAOYSA-N [4-fluoro-2-(methylamino)phenyl]-[3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]methanone Chemical compound CNC1=CC(F)=CC=C1C(=O)N1CC(C=2N=C(ON=2)C=2C(=CC=CC=2)F)CCC1 YMBKQJYKSFUBLO-UHFFFAOYSA-N 0.000 claims 1
- 206010001584 alcohol abuse Diseases 0.000 claims 1
- 201000007930 alcohol dependence Diseases 0.000 claims 1
- 208000025746 alcohol use disease Diseases 0.000 claims 1
- 208000029650 alcohol withdrawal Diseases 0.000 claims 1
- 208000006246 alcohol withdrawal delirium Diseases 0.000 claims 1
- 229940025084 amphetamine Drugs 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 125000006580 bicyclic heterocycloalkyl group Chemical group 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 201000006145 cocaine dependence Diseases 0.000 claims 1
- 230000019771 cognition Effects 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000024714 major depressive disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000003227 neuromodulating effect Effects 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 208000030459 obsessive-compulsive personality disease Diseases 0.000 claims 1
- 201000005040 opiate dependence Diseases 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 208000002851 paranoid schizophrenia Diseases 0.000 claims 1
- 208000022821 personality disease Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000019899 phobic disease Diseases 0.000 claims 1
- 229940126027 positive allosteric modulator Drugs 0.000 claims 1
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 claims 1
- 239000000700 radioactive tracer Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000000698 schizophrenic effect Effects 0.000 claims 1
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 0 CC1CCC(CONNN*)=CCC1 Chemical compound CC1CCC(CONNN*)=CCC1 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0510138A GB0510138D0 (en) | 2005-05-18 | 2005-05-18 | Novel compounds A4 |
| GBGB0601709.9A GB0601709D0 (en) | 2006-01-27 | 2006-01-27 | Novel compounds A4 |
| PCT/IB2006/001881 WO2006123255A2 (en) | 2005-05-18 | 2006-05-17 | Substituted oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008540635A JP2008540635A (ja) | 2008-11-20 |
| JP2008540635A5 true JP2008540635A5 (enExample) | 2009-07-02 |
Family
ID=37431638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008511821A Pending JP2008540635A (ja) | 2005-05-18 | 2006-05-17 | 代謝型グルタミン酸受容体の正のアロステリック調節因子としての置換されたオキシジアゾール誘導体 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20090215822A1 (enExample) |
| EP (1) | EP1893606A2 (enExample) |
| JP (1) | JP2008540635A (enExample) |
| KR (1) | KR20080027463A (enExample) |
| AU (1) | AU2006248655A1 (enExample) |
| BR (1) | BRPI0611423A2 (enExample) |
| CA (1) | CA2608014A1 (enExample) |
| EA (1) | EA015813B1 (enExample) |
| IL (1) | IL187186A0 (enExample) |
| MX (1) | MX2007014444A (enExample) |
| NO (1) | NO20076478L (enExample) |
| NZ (1) | NZ564254A (enExample) |
| WO (1) | WO2006123255A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0510140D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B2 |
| GB0510139D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| GB0510141D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B3 |
| GB0510142D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
| US7807706B2 (en) | 2005-08-12 | 2010-10-05 | Astrazeneca Ab | Metabotropic glutamate-receptor-potentiating isoindolones |
| GB0622202D0 (en) * | 2006-11-07 | 2006-12-20 | Addex Pharmaceuticals Sa | Novel compounds |
| TWI417100B (zh) * | 2007-06-07 | 2013-12-01 | Astrazeneca Ab | 二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途 |
| TW200911255A (en) | 2007-06-07 | 2009-03-16 | Astrazeneca Ab | Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841 |
| US7790760B2 (en) | 2008-06-06 | 2010-09-07 | Astrazeneca Ab | Metabotropic glutamate receptor isoxazole ligands and their use as potentiators 286 |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| WO2010098866A1 (en) | 2009-02-27 | 2010-09-02 | Supergen, Inc. | Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors |
| WO2010124055A1 (en) * | 2009-04-23 | 2010-10-28 | Merck Sharp & Dohme Corp. | 2-alkyl piperidine mglur5 receptor modulators |
| US8772301B2 (en) | 2009-12-18 | 2014-07-08 | Sunovion Pharmaceuticals, Inc. | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
| EP2531510B1 (en) | 2010-02-01 | 2014-07-23 | Novartis AG | Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists |
| AR080056A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de ciclohexil-amida como antagonistas de los receptores de crf |
| ES2527849T3 (es) | 2010-02-02 | 2015-01-30 | Novartis Ag | Derivados de ciclohexilamida como antagonistas del receptor de CRF |
| US20130210804A1 (en) * | 2010-10-25 | 2013-08-15 | Neville J. Anthony | Tricyclic mglur5 receptor modulators |
| WO2016065584A1 (en) * | 2014-10-30 | 2016-05-06 | Merck Sharp & Dohme Corp. | Piperidine oxadiazole and thiadiazole orexin receptor antagonists |
| US10538516B2 (en) | 2015-03-25 | 2020-01-21 | National Center For Geriatrics And Gerontology | Oxadiazole derivative and pharmaceutical containing same |
| WO2022069953A1 (en) * | 2020-09-29 | 2022-04-07 | Ranjith Siddaraj | Synthesis and characterization of (s)-3-(5- fluoropyridin-2-yl)-5-(piperidin-3-yl)-l,2,4-oxadiazole derivatives and their secretory phospholipase a2 (spla2) inhibitor activity |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3966748A (en) * | 1975-05-08 | 1976-06-29 | American Cyanamid Company | Para-fluorophenyl-N-heterocyclic substituted butanes |
| US20040132726A1 (en) * | 2002-08-09 | 2004-07-08 | Astrazeneca Ab And Nps Pharmaceuticals, Inc. | New compounds |
| EP1613615A2 (en) * | 2003-04-03 | 2006-01-11 | Merck & Co., Inc. | 4-ring imidazole derivatives as modulators of metabotropic glutamate receptor-5 |
| GB0325956D0 (en) * | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| NZ548693A (en) * | 2004-02-18 | 2010-05-28 | Astrazeneca Ab | Polyheterocyclic compounds and their use as metabotropic glutamate receptor antagonists |
| GB0510143D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
| GB0510141D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B3 |
| GB0510140D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B2 |
| GB0510142D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
| GB0510139D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| GB0622202D0 (en) * | 2006-11-07 | 2006-12-20 | Addex Pharmaceuticals Sa | Novel compounds |
-
2006
- 2006-05-17 KR KR1020077029359A patent/KR20080027463A/ko not_active Ceased
- 2006-05-17 EP EP06779843A patent/EP1893606A2/en not_active Withdrawn
- 2006-05-17 BR BRPI0611423-7A patent/BRPI0611423A2/pt not_active IP Right Cessation
- 2006-05-17 EA EA200702469A patent/EA015813B1/ru not_active IP Right Cessation
- 2006-05-17 CA CA002608014A patent/CA2608014A1/en not_active Abandoned
- 2006-05-17 JP JP2008511821A patent/JP2008540635A/ja active Pending
- 2006-05-17 WO PCT/IB2006/001881 patent/WO2006123255A2/en not_active Ceased
- 2006-05-17 NZ NZ564254A patent/NZ564254A/en not_active IP Right Cessation
- 2006-05-17 US US11/920,603 patent/US20090215822A1/en not_active Abandoned
- 2006-05-17 AU AU2006248655A patent/AU2006248655A1/en not_active Abandoned
- 2006-05-17 MX MX2007014444A patent/MX2007014444A/es not_active Application Discontinuation
-
2007
- 2007-11-06 IL IL187186A patent/IL187186A0/en unknown
- 2007-12-17 NO NO20076478A patent/NO20076478L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008540635A5 (enExample) | ||
| JP2008540637A5 (enExample) | ||
| JP2008540636A5 (enExample) | ||
| JP2008540634A5 (enExample) | ||
| AU2017286868B2 (en) | 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases | |
| AU2010339423B9 (en) | Therapeutic compounds and related methods of use | |
| JP5767393B2 (ja) | 新規二環式ピリジノン | |
| JP6370368B2 (ja) | Ｂｒｄ４阻害剤としてのインドリノン類似体 | |
| JP6085873B2 (ja) | トリアゾロピリダジン | |
| JP2014526435A5 (enExample) | ||
| KR101886945B1 (ko) | 감마-세크레타제 조절제로서의 크로멘 및 1,1a,2,7b-테트라히드로시클로프로파[c]크로멘 피리도피라진디온 | |
| JP6506833B2 (ja) | イミダゾピリダジン化合物 | |
| JP2019523233A5 (enExample) | ||
| WO2014154762A1 (en) | Dihydroquinazolinone analogues as brd4 inhibitors | |
| CA3066986A1 (en) | Dihydro-pyrrolo-pyridine derivatives | |
| WO2008150232A1 (en) | Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators - 841 | |
| WO2010132015A1 (en) | New compounds modulating gamma-secretase and their use in the treatment of alpha beta related pathologies, such as alzheimer's disease | |
| EP2462139B1 (en) | Sphingosine-1-phosphate receptor agonists | |
| CN106661017A (zh) | 新型二环性或三环性杂环化合物 | |
| JP2019535825A5 (enExample) | ||
| EP3644990A1 (en) | 5-(pyridin-3-yl)oxazole allosteric modulators of the m4 muscarinic acetylcholine receptor | |
| JP2019537592A5 (enExample) | ||
| JP2019537581A5 (enExample) | ||
| KR102148587B1 (ko) | 6,7-디히드로-5H-피라졸로[5,1-b][1,3]옥사진-2-카르복스아미드 화합물 | |
| JP2010229034A (ja) | 二環性ピロール誘導体 |